Patents Assigned to INSERM, Institut National de la Sante et de la Recherche Medicale
  • Patent number: 11912645
    Abstract: The invention is based on the discovery of a new bacterial compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Studying the mechanisms implicated in analgesic properties of the probiotic Escherichia coli strain Nissle 1917 (EcN), inventors characterized, the amino fatty acids produced by EcN, which display the Ecn analgesic properties. One of these compounds inhibits the hypersensitivity to colorectal distension induced by capsaicin, which is a very powerful nociceptive compound and acts via the GABA B receptor. Furthermore, inventors demonstrate that this compound is able to cross the cellular epithelial barrier (such as the intestinal epithelium). Thus, the invention relates to a lipopetide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: February 27, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, ECOLE NATIONALE VETERINAIRE DE TOULOUSE, UNIVERSITE PAUL SABATIER TOULOUSE III, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, UNIVERSITE DE MONTPELLIER, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER
    Inventors: Nicolas Cenac, Justine Bertrand-Michel, Teresa Perez-Berezo, Thierry Durand, Jean-Marie Galano, Julien Pujo, Eric Oswald, Patricia Martin, Pauline Le Faouder, Alexandre Guy
  • Publication number: 20240057969
    Abstract: An ultrasound probe holding device configured to attach to the head of an infant for transfontanellar imaging is disclosed, including a head pad configured to be in contact with the head of the infant and including a central opening, wherein the head pad is configured to receive an ultrasound probe; a pad squeezer, including a central opening and configured to cooperate with the head pad to allow an axial guidance of the head pad along a guidance axis substantially perpendicular to a surface tangent to the head of the infant; a device holder configured to be attached to the head of the infant and exert a downward force on the pad squeezer, along said guidance axis; and a repellent configured to exert a repellent force between the pad squeezer and the head pad when the device holder exerts the downward force on the pad squeezer.
    Type: Application
    Filed: December 13, 2021
    Publication date: February 22, 2024
    Applicants: ICONEUS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Centre National de la Recherche Scientifique, ECOLE SUPÉRIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Charlie Demene, Bruno-Felix Osmanski, Mickael Tanter, Jérôme Baranger, Olivier Baud
  • Patent number: 11905330
    Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: February 20, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉ
    Inventors: Guido Kroemer, José Manuel Bravo San Pedro
  • Patent number: 11903982
    Abstract: Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: February 20, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ETABLISSEMENT FRANCAIS DU SANG (EFS), UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
    Inventors: Rozenn Le Berre, Marie-Sarah Fangous, Gwenaelle Le Blay, Geneviève Hery-Arnaud, Rosyne Lagrafeuille
  • Publication number: 20240041423
    Abstract: A device tracking system for monitoring a target body structure and localizing a device inside the target body structure. The device tracking system includes: a control unit, a device having one steering element to be handled outside the target body structure and one steerable element to be introduced inside the target body structure, one probe to be removably secured to the patient, and one tracker to be secured to the steerable element. The control unit stores one ultrasound image of the target body structure. The probe and the tracker communicate, and the control unit is able to localize, in real time, the steerable element. The control unit displays, the stored ultrasound image and displays, in real time, the localisation of the at steerable element on the at least one ultrasound image.
    Type: Application
    Filed: December 10, 2021
    Publication date: February 8, 2024
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Antoine COUDERT, Olivier COUTURE, Vincent HINGOT
  • Publication number: 20240033366
    Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.
    Type: Application
    Filed: December 2, 2021
    Publication date: February 1, 2024
    Applicants: INSTITUT CURIE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COMMISSARIAT À L’ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (CEA), UNIVERSITE PARIS CITE, APHP (ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS)
    Inventors: Ludger JOHANNES, Anne BILLET, Jonathan ULMER, Denis SERVENT, Gilles MOURIER, Pascal KESSLER, Eric TARTOUR
  • Publication number: 20240034791
    Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: February 1, 2024
    Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –
    Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
  • Publication number: 20240008951
    Abstract: A computer-implemented method and a system for providing anatomical landmarks of a subject's body part using a set of measures previously acquired by an ultrasound device including at least one fiducial marker and an imaging sensor. Also, a non-transitory computer readable medium including instructions which, when the program is executed by a computer, cause the computer to carry out the method.
    Type: Application
    Filed: November 17, 2021
    Publication date: January 11, 2024
    Applicants: CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE BREST, UNIVERSITÉ DE BRETAGNE OCCIDENTALE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Guillaume DARDENNE, Hoel LETISSIER, Jérôme OGOR, Eric STINDEL
  • Patent number: 11865189
    Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 9, 2024
    Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Thierry Leveillard, Christo Kole, Jose-Alain Sahel
  • Patent number: 11866484
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 9, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Publication number: 20240002522
    Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERANN BIOTECHNOLOGY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE PARIS CITE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jerome GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
  • Publication number: 20240002521
    Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 4, 2024
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
  • Patent number: 11857532
    Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: January 2, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
  • Publication number: 20230393152
    Abstract: An identification of novel combinations of specific metabolites for neurodegenerative diseases for use as biomarkers in the early diagnosis of neurodegenerative diseases.
    Type: Application
    Filed: November 18, 2021
    Publication date: December 7, 2023
    Applicants: UNIVERSITE GRENOBLE ALPES, INSERM - Institut National de la Santé et de la Recherche Médicale
    Inventors: Sabrina BOULET, Florence FAUVELLE, David MALLET
  • Publication number: 20230384312
    Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.
    Type: Application
    Filed: October 22, 2021
    Publication date: November 30, 2023
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, UNIVERSITE D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Maria del Carmen MARTINEZ, Pierre BIGOT, Luisa VERGORI
  • Publication number: 20230372416
    Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.
    Type: Application
    Filed: October 8, 2021
    Publication date: November 23, 2023
    Applicants: UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Nathalie HEUZE-VOURC'H, Thomas SECHER, Muriel THOMAS
  • Patent number: 11823799
    Abstract: The present invention provides a powerful tool to identify personalized therapeutic strategies. In particular, the invention provides methods for determining therapeutically targetable dominant signaling pathways in a cancer sample from a subject affected with a solid cancer, determining a treatment protocol for the subject, selecting a subject for a therapy, determining whether the subject is susceptible to benefit from a therapy, predicting clinical outcome of the subject, treating the subject and/or predicting the sensitivity of a solid cancer to a therapy.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 21, 2023
    Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Dominique Bagnard, Aurore Fernandez, Laurent Jacob, Justine Fritz
  • Publication number: 20230364232
    Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.
    Type: Application
    Filed: September 17, 2021
    Publication date: November 16, 2023
    Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEUR
    Inventors: Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
  • Patent number: 11814683
    Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: November 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de Nantes
    Inventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
  • Publication number: 20230330440
    Abstract: Devices and methods for reversibly stimulating neuronal cells in a subject. The devices include a module for generating ultrasounds at 4 MHz or more to stimulate neuronal cells expressing mechanosensitive channels with the ultrasounds. The methods include expressing mechanosensitive channels into neuronal cells and exposing the cells to ultrasounds at 4 MHz or more. Also, the use of the methods or devices for visual restoration in a subject.
    Type: Application
    Filed: September 9, 2021
    Publication date: October 19, 2023
    Applicants: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Serge PICAUD, Sara CADONI, José-Alain SAHEL, Mickaël TANTER, Charlie DEMENE